News

Digital medical services platform Teladoc Health (NYSE:TDOC) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 4% year on year to $606.9 million. Next quarter’s revenue guidance of $589 million underwhelmed, coming in 6.5% below analysts’ estimates. Its GAAP loss of $0.21 per share was 15.5% above analysts’ consensus estimates.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Teladoc Health (TDOC) shares came under focus after the company reported second quarter 2026 results, which showed lower sales and a wider net loss, alongside fresh revenue and earnings guidance for the rest of the year. See our latest analysis for Teladoc Health. The earnings release and updated guidance appear to be weighing heavily on sentiment. Teladoc Health's share price return is down 28.32% over the past day and 24.02% over the past week, while the 1-year total shareholder return has...

Teladoc stock sinks on disappointing Q2 revenue and future guidance. Here’s why caution is warranted in buying the dip in TDOC shares today.

Moby summary of Teladoc Health, Inc.'s Q2 2026 earnings call

Teladoc Health (NYSE:TDOC) reported second-quarter results within its consolidated guidance range, supported by stronger-than-expected profitability in its Integrated Care segment, while lower cash-pay revenue at BetterHelp prompted the company to reduce its full-year revenue outlook. Consolidated

Demand for the mental health unit’s insurance offering accelerated faster than expected, eating into its cash pay business. The quarter marked an “unfortunate setback” for BetterHelp, one analyst said.

In late July 2026, Teladoc Health, Inc. reported second-quarter 2026 results showing sales of US$606.93 million and a net loss of US$38.91 million, with both revenue and per-share loss slightly weaker than the same period a year earlier. Over the first half of 2026, Teladoc’s sales declined to US$1.22 billion while its net loss narrowed to US$102.75 million, indicating that cost controls and efficiency measures may be helping even as top-line growth remains under pressure. We will now...

The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Teladoc (TDOC) delivered earnings and revenue surprises of +12.50% and -1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Digital medical services platform Teladoc Health (NYSE:TDOC) will be announcing earnings results this Wednesday after the bell. Here’s what investors should know.

HCA (HCA) delivered earnings and revenue surprises of +0.26% and 0.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

A new ChatGPT feature allows users to securely connect personal health data, enabling more personalized, context-aware responses to everyday health questions.

The latest trading day saw Teladoc (TDOC) settling at $9.65, representing a +2.33% change from its previous close.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Teladoc (TDOC) closed the most recent trading day at $9.21, moving +1.54% from the previous trading session.

Teladoc Health (TDOC) has drawn fresh attention after being removed from several Russell growth benchmarks, even as new partnerships with Walmart and the National Basketball Players Association are reshaping how investors view its virtual care footprint. See our latest analysis for Teladoc Health. Despite a 4.7% single day share price decline to about $9.07 after Teladoc Health was dropped from multiple Russell growth benchmarks, the stock has built strong short term momentum. It has a 30 day...

After a steep share price decline over the past five years, Teladoc Health now screens as cheap on several valuation checks, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model indicating that the stock trades at a discount to that estimate. Teladoc Health shareholders have seen the stock fall 93.9% over the past five years, which means even a modest shift in market expectations can have a large impact on perceived value. The push toward broader virtual care adoption,...

A number of stocks fell in the afternoon session after President Trump declared the Iran ceasefire "over" and vowed to strike again, driving oil higher and bond yields up in a risk-off rotation.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason — five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

A number of stocks jumped in the afternoon session after signs of renewed diplomatic talks between the U.S. and Iran boosted investor sentiment.

Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Teladoc (TDOC) reached $7.57 at the closing of the latest trading day, reflecting a +1.47% change compared to its last close.

Analyst sentiment shift and near term expectations Teladoc Health (TDOC) is back on investors’ radar after analysts turned more positive in their earnings estimates, even as they still expect a 26.32% year over year decline in the upcoming report. This change in sentiment, paired with a recent 1.44% gain that outperformed key indices, has focused attention on how the company’s virtual care and mental health businesses might shape near term performance. See our latest analysis for Teladoc...

Teladoc (TDOC) reached $7.03 at the closing of the latest trading day, reflecting a +1.44% change compared to its last close.

TDOC gains on Integrated Care growth, international expansion and cost cuts, but BetterHelp weakness and ongoing losses remain key challenges.